Dr. Julian Adams, President and CEO of @su2c.bsky.social, is at the @milkeninstitute.org today discussing innovations in #EarlyDetection and equitable cancer care. Panelists include @boehmjesse.bsky.social from @break-cancer.bsky.social, Ian Foulkes from @cancerresearchuk.org, and Maddie Musselman

Last week, Dr. Julian Adams, President and CEO of @su2c.bsky.social, spoke at the #LongwoodHealthcareLeaders #BostonCEO 2025. The event covered a wide range of topics, including health equity and patient access to care. It was attended by top leaders in healthcare and select Nobel Laureates.

Will Freed-Pastor from @danafarber.bsky.social gave a phenomenal presentation on cryptic #antigens and their potential as targets for TCR-based therapies at the @theaacr.bsky.social Special Conference in #PancreaticCancer Research.

The 18th @theaacr.bsky.social Conference on the Science of #HealthDisparities took place in Baltimore from September 18-21. A special session held on Saturday featured a panel discussion, grantees, advocates, and other members of the @su2c.bsky.social community. Thanks to all in attendance!

Michael Goggins, Maria Irene Canto, and a team of @su2c.bsky.social and @lustgarten.org funded researchers at @hopkinsmedicine.bsky.social have found a link between dilation of the #pancreatic duct and the development of #pancreaticcancer in high-risk individuals. www.ghadvances.org/article/S277...

The Data for Children's and Young People's Cancer Programme Award is a new partnership between @su2c.bsky.social and @cancerresearchuk.org to support data-driven solutions to common challenges in this space.
More information: cruk.ink/4njVxWU
Informational webinar: cruk.ink/4gdAcw9

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma Neoadjuvant ± adjuvant immunotherapy improves event-free survival (EFS) versus adjuvant immunotherapy alone for high-risk resectable Stage III melanoma. However, the optimal regimen balancing efficacy...

The @su2c.bsky.social Catalyst®-@genentech.bsky.social‬ Team lpublished the results of Arm C of the NeoACTIVATE trial in the European Journal of Cancer showing that neoadjuvant atezolizumab/tiragolumab is a promising treatment regimen in stage III melanoma www.ejcancer.com/article/S095...

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC - Nature Communications The approval of first line immune checkpoint blockade (ICB) has improved outcomes for patients with metastatic non-small cell lung cancer (mNSCLC), however, whether patients would benefit more from IC...

A study in NatureComms uses #ML and a clinicogenomic dataset generated by the @su2c.bsky.social -@ ‪@acscan.bsky.social‬ Lung Cancer Dream Team to improve immune checkpoint monotherapy or combination #immunotherapy-#chemotherapy for patients with #NSCLC. www.nature.com/articles/s41...

Request for Applications! The @su2c.bsky.social - @CRUK Prevention, Early Stage Detection, and Interception of Recurrence Challenge is now open! For more information, click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. standuptocancer.org/science/gran...

Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer Rousseau et al. show that tailored mutagenic chemical treatment induces a mismatch repair deficient genotype by epigenetic Msh2 silencing leading to potent immune response in immunoresistant tumor mod...

According to a paper published in ‪@cp-cancercell.bsky.social‬ by the @su2c.bsky.social‬ Colorectal Cancer Dream, they have been able to use mutagenic agents to engineer an MMRd genotype in immunoresistant cells to generate an immunogenic phenotype
www.cell.com/cancer-cell/...

The GBM chatbot is going live on the @su2c.bsky.social website on 7/16. This AI companion was developed by Jason Binder after his wife was diagnosed with glioblastoma to help patients and family members to understand glioblastoma, explore options, and feel less alone on this journey. #GBMDay

@su2c.bsky.social Convergence 3.1416 Research Team member Raul Rabadan published a review in @CR_AACR examining examples of noncoding mutations in cancer and comparing key AI models developed over the last decade for uncovering cancer-associated noncoding mutations. aacrjournals.org/cancerres/ar...

A project initiated by the @su2c.bsky.social Breast Cancer Dream Team was published in npj precision oncology utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer www.nature.com/articles/s41...

Grant and Award Opportunities | Stand Up To Cancer® Stand Up To Cancer (SU2C) grants and awards fund cancer research projects that address critical problems in patient care and deliver near-term patient benefit through both individual and collaborative...

New Request for Applications! The @su2c.bsky.social Lung Cancer Early Detection Challenge is open! For information, please click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. #LungCancer #EarlyDetection #StandUpToCancer standuptocancer.org/science/gran...

Genomic landscape of multiple myeloma and its precursor conditions - Nature Genetics The genomic features of precursor conditions of multiple myeloma provide multiple biological insights into disease origins and evolution, together with opportunities to identify those at highest risk ...

The @su2c.bsky.social‬ Multiple Myeloma Dream Team published in ‪@natgenet.nature.com describing their MM precursor genomic map in order to better inform risk assessment and monitoring of MM precursor conditions. www.nature.com/articles/s41...

Check out the upcoming New York Academy of Sciences Frontiers in Cancer Immunology Symposium. The event features several current and former @SU2C – funded researchers including @bengrbm.bsky.social, Jim Allison, Antoni Ribas, Taha Merghoub, and Padmanee Sharma. #immunology #cancer

High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples - Nature Biomedical Engineering A platform for profiling single-cell density reveals insights into the regulation of cell density homeostasis and patient drug responses.

A new method shows unexpected behavior in molecular crowding during cell state transitions suggests density as a biomarker for precision medicine per a paper in @natbiomedeng.nature.com‬ from @su2c.bsky.social‬ Convergence 3.1416 Research Teams Scott Manalis ‪@mit.edu‬ www.nature.com/articles/s41...

Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer Noninvasive mutation-based and fragmentation-based cfDNA approaches can identify response to therapy in pancreatic cancer.

cfDNA approaches can identify therapeutic response of #pancreaticcancer patients per a paper from Victor Velculescu of the @su2c.bsky.social‬-@nkinl.bsky.social and @su2c.bsky.social y.social‬-@lungusa.bsky.social‬-@lungevity.bsky.social Dream Teams https://www.science.org/doi/10.1126/sciadv.ads5002

PRDM16-dependent antigen-presenting cells induce tolerance to gut antigens - Nature A subset of antigen-presenting cells of myeloid origin that require PRDM16 and RORγt regulates T cell function to enable immune tolerance of food and commensal gut microorganisms.

Work from the ‪@su2c.bsky.social‬Convergence 3.1416 Research Team led by Dan Littman from NYU and a Sharp Award was published in @nature.com‬ describing how dendritic cells are able to regulate T cell responses to food and microbes and contribute to food tolerance www.nature.com/articles/s41...

Gerrit Meijer from the @su2cscience.bsky.social-#KWF MEDOCC team presented the Team’s work in developing the multi-target FIT test for colorectal cancer at the @nkinl.bsky.social Early Cancer Detection Conference #StandUpToCancer #NetherlandsCancerInstitute #colorectalcancer

Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...

80% of patients with early stage dMMR solid tumors treated with dostarlimab avoided surgery, chemotherapy or radiation after treatment per a paper published in @nejm.org by Andrea Cercek @mskcancercenter.bsky.social of the @su2c.bsky.social Colorectal Cancer Dream Team
www.nejm.org/doi/full/10....

The @su2c.bsky.social Catalyst @genentech.bsky.socia Team published in the Journal for ImmunoTherapy of Cancer a low rate of distant metastasis differences in gut microbiome structure in patients enrolled in the NeoACTIVATE trial jitc.bmj.com/content/13/4...

Congratulation to the 2025 class of Fellows of the @theaacr.bsky.social Academy and @su2cscience.bsky.social community members Nina Bhardwaj from Mount Sinai, Stephan Grupp and Robert Vonderheide@penncancer.bsky.social, Ari Melnick @weillcornell.bsky.social, William Sellers @broadinstitute.org!!

In February, members of the #StandUpToCancer - Van Andel Institute #Epigenetics Dream Team, Ben Youngblood from St. Jude Children's Research Hospital, and Kirsten Grønbaek from Rigshospitalet, presented at the AACR DNA #Methylation, Clonal Hematopoiesis, and #Cancer Special Conference in San Diego.

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer - Nature In a phase 1 trial, patients with pancreatic ductal adenocarcinoma who were treated with surgery and bespoke neoantigen mRNA vaccines combined with anti-PD-L1 and chemotherapy exhibited marked lo...

An new publication in @Nature by SU2C Convergence Team leaders @thevinodlab.bsky.social @bengrbm.bsky.social @mskcancercenter.bsky.social showed an individualized neoantigen mRNA vaccine for #pancreaticcancer led to prolonged survival and effector T cell responses www.nature.com/articles/s41...

Post Next 50 50 people shaping our society in 2025

Congratulations to @su2cscience.bsky.social-@lustgarten.org Convergence Team Co-Leader @TheVinodLab on being named to the inaugural edition of the @washingtonpost.com Post Next 50, a list of up-and-coming changemakers shaping society in 2025! wapo.st/VinodBalacha...

Thank you AACR CEO Dr. Margaret Foti, SU2C co-founder Sherry Lansing, and SU2C Scientific Advisory Committee Chair Dr. William Nelson for speaking and to everyone who joined us at the virtual #StandUpToCancer Community Gathering today. We look forward to meeting again! 🙌

We were honored to hear from keynote speakers Drs. Trey Ideker, Melissa Davis, Kevan Shokat, & Mark McClellan who each presented at the virtual #StandUpToCancer Community Gathering. Topics were AI in cancer research, cancer inequities, KRAS mutation, healthcare reform, & more.

Today, our #StandUpToCancer researchers met virtually to discuss the latest in cutting-edge science & share their progress at the SU2C Community Gathering. As SU2C President & CEO Dr. Julian Adams says, we have no doubt in our goal to save more lives from this terrible disease. 💪